Gemcitabine–oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed

BACKGROUND: There has been no previous study on the activity of gemcitabine in combination with oxaliplatin (GemOx) for castration-resistant prostate cancer (CRPC). METHODS: The GemOx was preclinically tested for cytotoxic activity in human prostate cancer cell lines. Clinically, patients with CRPC...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Lee, J-L, Ahn, J-H, Choi, M K, Kim, Y, Hong, S-W, Lee, K-H, Jeong, I-G, Song, C, Hong, B-S, Hong, J H, Ahn, H
Format: Artigo
Sprache:Inglês
Veröffentlicht: Nature Publishing Group 2014
Schlagworte:
Translational Therapeutics
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4021534/
https://ncbi.nlm.nih.gov/pubmed/24736579
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2014.204
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge